TG Therapeutics (NASDAQ:TGTX) Stock Price Crosses Above Fifty Day Moving Average – Time to Sell?

TG Therapeutics, Inc. (NASDAQ:TGTX) passed above its fifty day moving average during trading on Monday. The stock has a fifty day moving average of $54.70 and traded as high as $55.49. TG Therapeutics shares last traded at $54.79, with a volume of 1,187,439 shares traded.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Zacks Research upgraded TG Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 6th. JPMorgan Chase & Co. boosted their target price on TG Therapeutics from $65.00 to $72.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. B. Riley Financial boosted their target price on TG Therapeutics from $55.00 to $86.00 and gave the company a “buy” rating in a research note on Monday, July 27th. Weiss Ratings lowered TG Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research report on Friday, October 23rd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $78.00 price target on shares of TG Therapeutics in a research note on Tuesday, September 1st. Six analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, TG Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $63.00.

TG Therapeutics Price Performance

The company has a quick ratio of 3.72, a current ratio of 4.27 and a debt-to-equity ratio of 1.23. The company has a market capitalization of $8.79 billion, a P/E ratio of 20.95, a P/E/G ratio of 2.29 and a beta of 1.80. The company’s 50-day simple moving average is $54.99 and its 200 day simple moving average is $43.43.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.31 by ($0.26). TG Therapeutics had a return on equity of 73.49% and a net margin of 55.22%. The business had revenue of $240.34 million for the quarter, compared to analyst estimates of $229.77 million. During the same quarter last year, the company earned $0.17 EPS. The business’s revenue for the quarter was up 70.2% compared to the same quarter last year. As a group, sell-side analysts expect that TG Therapeutics, Inc. will post 0.92 earnings per share for the current fiscal year.

Insider Buying and Selling

In other TG Therapeutics news, Director Laurence Charney sold 5,000 shares of the firm’s stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $54.96, for a total transaction of $274,800.00. Following the transaction, the director directly owned 168,640 shares in the company, valued at $9,268,454.40. This trade represents a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 8.87% of the stock is owned by insiders.

Institutional Trading of TG Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Stronghold Wealth Management L.L.C. raised its stake in shares of TG Therapeutics by 6.3% in the 3rd quarter. Stronghold Wealth Management L.L.C. now owns 3,922 shares of the biopharmaceutical company’s stock valued at $219,000 after acquiring an additional 231 shares in the last quarter. Farther Finance Advisors LLC lifted its holdings in TG Therapeutics by 45.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 993 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 312 shares during the last quarter. EverSource Wealth Advisors LLC boosted its position in TG Therapeutics by 51.9% during the first quarter. EverSource Wealth Advisors LLC now owns 1,068 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 365 shares during the period. Choreo LLC boosted its position in TG Therapeutics by 3.7% during the third quarter. Choreo LLC now owns 10,811 shares of the biopharmaceutical company’s stock worth $603,000 after purchasing an additional 384 shares during the period. Finally, Chiron Capital Management LLC grew its holdings in TG Therapeutics by 10.5% during the third quarter. Chiron Capital Management LLC now owns 4,200 shares of the biopharmaceutical company’s stock valued at $234,000 after purchasing an additional 400 shares during the last quarter. Institutional investors and hedge funds own 58.58% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and delivering medicines for B-cell diseases, including multiple sclerosis and certain blood cancers. The company’s research and development programs are centered on therapies that target B cells and the immune system.

TG Therapeutics’ primary marketed product is BRIUMVI (ublituximab-xiiy), an anti-CD20 monoclonal antibody approved in the United States for the treatment of relapsing forms of multiple sclerosis in adults.